Tiny antibody tools to target the cell communication protein Cx43
Development of a nanobody tool kit to study connexin channels
Researchers are making very small engineered antibodies that latch onto a cell protein called Cx43 to help address problems in nerve and muscle health for people with conditions like ALS.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-11171553 on NIH RePORTER |
What this research studies
This project will create tiny antibody-like molecules called nanobodies that bind the human Cx43 protein involved in cell-to-cell communication. Researchers will immunize llamas with short pieces of the Cx43 protein, use the llamas' immune cells to build a library of nanobody sequences, and pick the nanobodies that best stick to undocked hemichannels versus fully formed gap junctions. The selected nanobodies will be tested in lab models to check how specifically they bind, how well they penetrate tissues, and how they affect channel function. The work is lab-based at UC Davis and does not require patient visits for this phase.
Who could benefit from this research
Good fit: People with ALS or other disorders linked to Cx43 or gap junction dysfunction would be the most relevant group for future testing or follow-up studies.
Not a fit: Patients whose conditions are unrelated to Cx43 or gap junction problems are unlikely to see direct benefit from this specific work.
Why it matters
Potential benefit: If successful, these nanobody tools could let scientists distinguish and selectively target harmful Cx43 hemichannels while leaving normal gap junctions intact, opening the door to more precise therapies for ALS and other Cx43-related conditions.
How similar studies have performed: Nanobodies have been useful in other medical areas, but using them to tell apart undocked hemichannels from gap junctions is a novel and relatively untested application.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Contreras, Jorge Enrique — University of California at Davis
- Study coordinator: Contreras, Jorge Enrique
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.